Company intelligence / Profile preview

BioCreatrix

Ownership: Private
Employees: ~10
Development stage: Other

Overview

BioCreatrix is developing a portfolio of precision medicine solutions including personalized cancer vaccines based on patient-specific tumor neoantigens, advanced liquid biopsy diagnostics for early disease detection, and preventative screening tools. The company leverages integrated technology platforms to rapidly translate scientific discoveries into practical healthcare solutions. Clinical results are not yet published but the company is advancing programs toward clinical trials.

Therapeutic areas: NeurologyOncology
Modalities: VaccineDiagnostic deviceSmall moleculeCell therapy
Industry: Biotech

Drug pipeline

3 assets

CAR-NK IND Pipeline 6

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

Provides services to local & international oncologists & pharmaceutical companies via Telotech

Beyond the preview

Go deeper on BioCreatrix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioCreatrix.

Explore the full profile